995 related articles for article (PubMed ID: 22466618)
1. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
[TBL] [Abstract][Full Text] [Related]
3. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
[TBL] [Abstract][Full Text] [Related]
4. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
Michl P; Gress TM
Gut; 2012 Oct; 61(10):1377-9. PubMed ID: 22661496
[No Abstract] [Full Text] [Related]
5. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ;
J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
[TBL] [Abstract][Full Text] [Related]
9. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Rückert F; Grützmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA
Science; 2009 Jun; 324(5933):1457-61. PubMed ID: 19460966
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
[TBL] [Abstract][Full Text] [Related]
12. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
13. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Doherty GJ; Tempero M; Corrie PG
Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360
[TBL] [Abstract][Full Text] [Related]
14. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Neesse A; Frese KK; Bapiro TE; Nakagawa T; Sternlicht MD; Seeley TW; Pilarsky C; Jodrell DI; Spong SM; Tuveson DA
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12325-30. PubMed ID: 23836645
[TBL] [Abstract][Full Text] [Related]
15. PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Gourd E
Lancet Oncol; 2018 Feb; 19(2):e81. PubMed ID: 29276021
[No Abstract] [Full Text] [Related]
16. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
[TBL] [Abstract][Full Text] [Related]
18. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.
Seki T; Saida Y; Kishimoto S; Lee J; Otowa Y; Yamamoto K; Chandramouli GV; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
Neoplasia; 2022 Aug; 30():100793. PubMed ID: 35523073
[TBL] [Abstract][Full Text] [Related]
19. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
